Document:

EX-10.2

 Exhibit 10.2 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH
(i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 This document is an
English translation of a document prepared in German. In preparing this document, an attempt has been made to translate as literally as possible without jeopardizing the overall continuity of the text. Inevitably, however, differences may occur in
translation and if they do, the German text will govern by law. 
 In this translation, German legal concepts are expressed in English
terms and not in their original German terms. The concepts concerned may not be identical to concepts described by the English terms as such terms may be understood under the laws of other jurisdictions. 

Confirmation about the agreement regarding [***] development results / 

License Agreement dated 01.01.2015 (“WP-1-Contract”) 

Master Agreement for Research Services dated 01.01.2015 entitled „Rahmenvertrag für Forschungsleistungen” (“WP-3-Contract”) 
 TRON gGmbH, BioNTech AG and BioNTech RNA Pharmaceuticals GmbH herewith confirm
their agreement regarding results related to the development of [***], including methods, processes, [***], each for bioinformatic selection processes of mutations for the vaccine design of individualized vaccines and any and all intellectual
property rights relating thereto, including, without limitation, patents, copyrights or trade secrets (hereinafter together referred to as “[***] Development Results”): 

1) All [***] Development Results that were created as a result of the cooperation between the entities of the BioNTech Group and TRON gGmbH (including any
contribution by the Johannes-Gutenberg-Universität Mainz or the Universitätsmedizin der Johannes Gutenberg-Universität Mainz, collectively referred to as “University”) until 31.12.2014 are governed by the License Agreement
dated 01.01.2015 (“WP-1-Contract”). To the extent such [***] Development Results are not claimed by BioNTech Patents or by Joint Patents as defined by sections
1.6 or 1.18 WP-1-Contract, respectively, they shall be deemed “BioNTech Development Results” as defined by section 1.3 WP-1-Contract; below section 9 relating to rights of third parties remains unaffected. 
 2) All [***] Developments
Results that were or will be created as a result of (i) the cooperation between the entities of the BioNTech Group and TRON gGmbH or (ii) the research license according to section 3.6 WP-1-Contract, in each case as of 01.01.2015 until 31.12.2016 solely by TRON gGmbH or by TRON gGmbH together with BioNTech AG or BioNTech RNA Pharmaceuticals GmbH are governed by the Master Agreement for
Research Services dated 01.01.2015 (“WP-3-Contract”). Such [***] Development Results shall be deemed “Results” as defined by section 1.3 WP-3-Contract and pursuant to section 4.2 WP-3, TRON gGmbH hereby assigns to BioNTech AG all right, title and interest in and to such
Results. For the avoidance of doubt, to the extent the rights in such Results cannot be assigned pursuant to section 4.2 WP-3-Contract under applicable law, TRON gGmbH
hereby grants to BioNTech AG or its respective affiliate an exclusive, perpetual and irrevocable license, with the right to grant sublicenses, under such Results. 

3) TRON gGmbH confirms that, to its knowledge, the [***] Development Results created as of the date of this agreement do not comprise results to which third
parties (other than the Universities, any 

 
affiliate of a party, or GANYMED Pharmaceuticals AG) have any rights (including industrial property rights and copyrights). Pursuant to section 6.2 WP-1-Contract and section 6.2 WP-3-Contract, TRON gGmbH and BioNTech AG will inform each other about industrial property rights
or copyrights of third parties which they are aware of or which become known to them and which might be violated by the use of the [***] Development Results. 

4) BioNTech AG grants TRON gGmbH and its affiliated entities (where TRON holds at least 50 % equity) – the affiliated entities solely for as long as
those entities are so affiliated with TRON gGmbH –under the [***] Development Results (insofar deviant to section 4.1 WP-3-Contract): 

 

	 	(a)	 A non-exclusive,
non-transferable, non-sublicensable, cost-free license solely for internal, non-commercial research purposes; 

and 
  

	 	(b)	 A non-exclusive,
non-transferable, non-sublicensable, cost-free, perpetual and irrevocable license for research, development and performance of diagnostic services, to the extent that these diagnostic services are provided
solely to direct patient customers and medical health care centers solely for the clinical care of patients, but not to any other entities, including drug manufacturers or manufacturers of medical devices and research-based pharmaceutical companies;
for the avoidance of doubt, the diagnostic services shall not include the provision of any analysis or results related to [***]identification. 

TRON gGmbH shall notify BioNtech AG immediately, once it or any of its affiliates as defined above commences providing diagnostic services.

 TRON gGmbH shall not use the [***] Development Results (including any improvements that include [***] Development Results) outside the
scope of the licenses granted under (a) and (b) above. 
 5) TRON gGmbH receives one-time payments for all
rights granted or transferred to BioNTech AG resp. BioNTech RNA Pharmaceuticals GmbH and all performed services by TRON gGmbH related to [***] Development Results, in addition to the royalty obligations under the WP-1-Contract and WP-3-Contract, according to the following milestones: 

 

	 	a)	 [***] due after the transfer of the respective patent applications, including any documents related to the
patent applications, within the assigned [***] Development Results. 

  

	 	b)	 [***] due after transfer of any and all data, [***] and documents within the assigned [***] Development Results
within a reasonable term determined by BioNTech of not less than 30 days; the parties shall prepare in good faith a Know-How and Material Transfer List identifying the items for such transfer, without such
list being limiting in any way of the obligation, of TRON gGmbH, to transfer such [***] Development Results. 

  

	 	c)	 [***] due after use of relevant methods and software, generated under the participation of TRON gGmbH, on at
least 1,000 patients. 

 Additionally, BioNTech AG or BioNTech RNA Pharmaceuticals GmbH respectively takes over all external patent costs
which will accrue to TRON gGmbH after the signing of this agreement. Any other costs of TRON gGmbH, that accrued in connection to the transfer of the [***] patents and patent applications until 31.08.2017, which are costs for installation, data and know-how transfer according to the aforementioned Know-How and Material Transfer List, consulting, introduction and training by TRON gGmbH, are included in the aforementioned
compensation. 

  
 2 

 6) All [***] Developments Results that will be created as a result of the [***] related cooperation between
the entities of the BioNTech Group and TRON gGmbH as of 01.01.2017 are governed by the WP-3-Contract. Such [***] Development Results shall be deemed “Results”
as defined by section 1.3 WP-3-Contract. For the avoidance of doubt, sections 2, second sentence of 3 and -4 above shall also
apply to these [***] Development Results. 
 7) The [***] Development Results according to above sections 1, 2 and 6 are “Confidential
Information” according to the WP-1-Contract and WP-3-Contract, respectively, and
TRON gGmbH shall keep them confidential, shall not disclose them (as far as not already disclosed for the purpose of the respective patent applications named under section 5 a) to third parties and shall not publish them, and shall only use them for
the purposes of the licenses according to above section 4. For scientific publications, presentations and talks regarding development work, TRON will, in advance and in a timely manner, align with BioNTech and ensure, that
BioNTech can prepare and file patent applications prior to such publication. Upon BioNTech ́s request, TRON will exclude potentially critical information from the planned publications. Scientific publications shall be made according
to international standards and scientific publication ethics under consideration of the interest of the parties involved in the [***] Development Results. 

8) The parties agree to negotiate in good faith a transfer or license agreement in relation to any and all neoepitope related improvements to [***]
Development Results independently developed by TRON gGmbH (alone or in cooperation with the University), under which TRON gGmbH shall transfer any and all rights, or grant an exclusive license, to BioNTech AG for such improvements. 

9) The parties agree that, among the parties, this agreement takes precedence over the
WP-1-Contract and the WP-3-Contract; the rights of the other parties to the WP-1-Contract and the WP-3-Contract remain unaffected. 

 

			
	 Mainz 15.9.2016
	  	Mainz 15.9.2016
		
	 [***]
	  	[***]
	 TRON gGmbH
	  	TRON gGmbH
	 [***]
	  	[***]
	 Managing Director
	  	Managing Director

 Mainz 15.9.2016 
 [***] 

BioNTech AG 
 [***] 

Management Board 
 Mainz 15.9.2016 

[***] 
 BioNTech RNA Pharmaceuticals GmbH 

[***] 
 Managing Director 

  
 3EX-10.3

  
 Exhibit 10.3

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS 

BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM 

TO THE COMPANY IF PUBLICLY DISCLOSED 

EXECUTION COPY 
 Strictly Confidential 

 
  

SUPPLEMENTARY AGREEMENT 

FOR [***] DEVELOPMENTS 

TO THE 
 MASTER
AGREEMENT FOR RESEARCH SERVICES 
 DATED 1 JANUARY 2015 

 
  

between 
 TRON-Translationale
Onkologie 
 an der Universitätsmedizin 

of Johannes Gutenberg – Universität Mainz gemeinnützige GmbH 

Freiligrathstraße 12 
 D-55131 Mainz 
 hereinafter referred to as “TRON” 

and 
 BioNTech AG 

An der Goldgrube 12 
 D-55131 Mainz 
 hereinafter referred to as “BIONTECH” 

as well as the following subsidiaries of BIONTECH: 

BioNTech RNA Pharmaceuticals GmbH 

An der Goldgrube 12 
 D-55131 Mainz 
 and 

  
 Page 1 

 EXECUTION COPY 
  

BioNTech Diagnostics GmbH 
 An der
Goldgrube 12 
 D-55131 Mainz 

and 
 BioNTech Protein
Therapeutics GmbH 
 An der Goldgrube 12 

D-55131 Mainz 

and 
 BioNTech Cell &
Gene Therapies GmbH 
 An der Goldgrube 12 

D-55131 Mainz 

and 
 BioNTech Innovative
Manufacturing Services GmbH 
 (formerly EUFETS GmbH) 

Vollmersbachstraße 66 

D-55743 Idar-Oberstein 
 and 

JPT Peptide Technologies GmbH 

Volmerstrasse 5 
 D-12489 Berlin 
 hereinafter jointly referred to as the “BIONTECH SUBSIDIARIES” 

BIONTECH and the BIONTECH SUBSIDIARIES are hereinafter jointly referred to as the 

“BIONTECHGROUP” 

  
 Page 2 

 EXECUTION COPY 
  

PREAMBLE 
  

	A.	 TRON and the companies of the BIONTECH GROUP concluded a master agreement for research services on 01 January
2015 (i.e. the “Rahmenvertrag für Forschungsleistungen”, hereinafter referred to as the “MASTER AGREEMENT”). 

  

	B.	 On 15 September 2016, TRON and BIONTECH and BioNTech RNA Pharmaceuticals GmbH concluded a Confirmation of the
Agreement for [***] (i.e. the “Bestätigung der Übereinkunft für [***]”, hereinafter referred to as the “[***] AGREEMENT”). The [***] AGREEMENT shall apply unchanged and remain in effect, except for section 8
thereof, which shall have no further effect upon the execution of this Supplementary Agreement. 

  

	C.	 Effective as of [***], BIONTECH and BioNTech RNA Pharmaceuticals GmbH concluded an exclusive collaboration
agreement for the development, production and marketing of [***] with [***] (hereinafter referred to as “[***] COOPERATION”). In the context of the [***] COOPERATION, BIONTECH and BioNTech RNA Pharmaceuticals GmbH intend to engage TRON to
provide PROJEKTLEISTUNGEN (as defined in the MASTER AGREEMENT and hereinafter referred to as the “PROJECT SERVICES”) on the basis of the MASTER AGREEMENT, and TRON is willing to accept this engagement. 

 

	D.	 With this Supplementary Agreement, the PARTEIEN (as defined in the MASTER AGREEMENT and hereinafter referred to
as the “PARTIES”) intend a) to define certain areas of activity of TRON, in particular regarding [***] COOPERATION, as being contracted for generally under the MASTER AGREEMENT, and b) to conclude the transfer and licensing agreement, as
provided in clause 8 of the [***] AGREEMENT. 

  
 Page 3 

 EXECUTION COPY 
  

 

	1.	 Definition of Terms 

 

	1.1	 Any terms in capital letters, which are not defined otherwise in this Supplementary Agreement, shall have the
meaning assigned to them in the MASTER AGREEMENT. 

  

	2.	 [***] COOPERATION FIELD and other PROJECTS 

 

	2.1	 “[***] COOPERATION FIELD” within the meaning of this Supplementary Agreement means all activities
performed for the purposes of the research or development of [***], including the development of formulations, biological principles, methods, processes, [***]. The [***] COOPERATION FIELD also includes any activities performed (i) pursuant to
the licenses under the patents listed under Attachment 2.1 and related BioNTech Development Results (defined as “BioNTech-Entwicklungsergebnisse” under Section 1.3 of the LICENSE
AGREEMENT) granted under section 3.6 of the LICENSE AGREEMENT, (ii) pursuant to the licenses granted under section 4(a) or 4(b) of the [***] AGREEMENT or section 4.1 or 4.2 of this Supplementary Agreement or (iii) otherwise using or
incorporating the RESULTS (as defined by section 1.3 of the MASTER AGREEMENT and as amended by the [***] Agreement and this Supplementary Agreement), which includes the [***] DEVELOPMENT RESULTS (as defined by the [***] AGREEMENT), in each case,
regardless of whether such activities are performed for the purposes of the research or development of [***]. 

  

	2.2	 Research and Development Activities 

 

	2.2.1	 Without limiting the MASTER AGREEMENT or the [***] AGREEMENT, the PARTIES agree that, all research and
development activities of TRON and/or its affiliated companies (minimum stake of 50 % held by TRON, hereinafter referred to as “TRON AFFILIATED COMPANIES”) performed in the [***] COOPERATION FIELD (but are not otherwise covered by the
MASTER AGREEMENT as PROJECT SERVICES or by the [***] AGREEMENT as regards to the [***] DEVELOPMENT RESULTS) shall be deemed to be contracted for under the MASTER AGREEMENT and, thus, constitute PROJECT SERVICES under the MASTER AGREEMENT, regardless
of whether the research and development activities are carried out (i) during the term of the term of this 

  
 Page 4 

 EXECUTION COPY 
  

	 	Supplementary Agreement or (ii) earlier at any time from 01.01.2015. As regards to the development and research activities of the TRON AFFILIATED COMPANIES, sentence 1 of this Section 2.2.1 shall only apply
insofar as the TRON AFFILIATED COMPANIES perform such activities (i) pursuant to the licenses while the patents listed under Attachment 2.1 and related BioNTech Development Results (defined as
“BioNTech-Entwicklungergebnisse” under Section 1.3 of the LICENSE AGREEMENT) granted under section 3.6 of the LICENSE AGREEMENT, (ii) pursuant to the licenses granted under section 4(a) or 4(b) of the [***] AGREEMENT or section
4.1 or 4.2 of this Supplementary Agreement or (iii) otherwise using or incorporating the RESULTS (as defined by section 1.3 of the MASTER AGREEMENT and as amended by the [***] Agreement and this Supplementary Agreement), which includes the
[***] DEVELOPMENT RESULTS (as defined by the [***] AGREEMENT). 

 For the purposes of this Supplementary Agreement, “TRON
ACTIVITIES” shall mean all research and development activities of TRON and/or TRON AFFILIATES COMPANIES performed in the [***] COOPERATION FIELD that are (i) contracted for under the MASTER AGREEMENT as PROJECT SERVICES (e.g,
such activity was performed as part of an individual order pursuant to section 2.1 or as part of the overall project plan pursuant to section 2.2 of the MASTER AGREEMENT) or (ii) otherwise deemed contracted for under the MASTER AGREEMENT as
PROJECT SERVICES pursuant to this section 2.2.1. 
  

	2.2.2	 Therefore, all results (including any and all intellectual property rights, including, without limitation,
patents, copyrights or trade secrets) generated by TRON or TRON AFFILIATED COMPANIES from the TRON ACTIVITIES during the term of this Supplementary Agreement alone or jointly with one or more PARTIES or third parties as permitted under this
Supplementary Agreement shall constitute ERGEBNISSE (hereinafter referred to as “RESULTS”) for all purposes of the MASTER AGREEMENT and this Supplementary Agreement, and TRON will immediately inform BIONTECH of such RESULTS. TRON herewith
transfers all associated rights in accordance with section 4.2 of the MASTER AGREEMENT to BioNTech RNA Pharmaceuticals GmbH; provided, however: 

(a) insofar as the rights to such RESULTS cannot be transferred in accordance with section 4.2 of the MASTER AGREEMENT pursuant to
applicable laws, TRON herewith grants BioNTech RNA Pharmaceuticals GmbH an exclusive, perpetual, irrevocable and transferable license under these RESULTS (including any and all intellectual property rights), with the right to grant sub-licenses; and 

  
 Page 5 

 EXECUTION COPY 
  

(b) insofar as the rights to such RESULTS were generated by one or more third parties in collaboration with TRON or TRON AFFILIATED COMPANIES
as permitted under this Supplementary Agreement, TRON herewith grants to BioNTech RNA Pharmaceuticals GmbH a non-exclusive, royalty-free, fully paid, perpetual, irrevocable, and transferable license
under any such results (including any and all intellectual property rights), with the right to grant sub-licenses in lieu of transferring such results in accordance with section 4.2 of the MASTER AGREEMENT. 

TRON shall ensure that TRON is also entitled to transfer any rights, or grant any licenses, as applicable, to results and improvements
(including any and all intellectual property rights) of the TRON AFFILIATED COMPANIES to BioNTech RNA Pharmaceuticals GmbH pursuant to this Supplementary Agreement. TRON confirms that, to its knowledge, such RESULTS generated as of the effective
date of this Supplementary Agreement do not comprise results to which THIRD PARTIES have any rights (including industrial property rights and copyrights). 
  

	2.2.3	 Without prejudice to the above, the PARTIES agree, where possible with respect to TRON ACTIVITIES that were not
contracted for under the MASTER AGREEMENT as PROJECT SERVICES, to also conclude individual orders pursuant to section 2.1 of the MASTER AGREEMENT to cover such TRON ACTIVITIES or to define such TRON ACTIVITIES as being included in the overall
project plan pursuant to section 2.2 of the MASTER AGREEMENT. 

  

	2.3	 In deviation from section 2.5 of the MASTER AGREEMENT, the consent to the engagement of
UNIVERSITÄTSMEDIZIN (hereinafter referred to as “UNIVERSITY MEDICINE”) or the UNIVERSITÄT MAINZ (hereinafter referred to as “UNIVERSITY MAINZ”) as a subcontractor shall not be deemed to be given for any individual
orders pursuant to section 2.1 of the MASTER AGREEMENT for any PROJECT SERVICES within the [***] COOPERATION FIELD, which means that TRON, in the [***] COOPERATION FIELD, always has to obtain the prior written consent of the relevant company of the
BIONTECH GROUP in order to engage a third party (other than any TRON AFFILIATED COMPANY as permitted under Section 6) as a subcontractor. 

  

	2.4	 With respect to research and development activities of TRON and/or TRON AFFILIATES COMPANIES performed outside
the [***] COOPERATION 

  
 Page 6 

 EXECUTION COPY 
  

FIELD that are contracted for under the MASTER AGREEMENT as PROJECT SERVICES, the terms and conditions of the MASTER AGREEMENT shall continue
to apply unchanged. 
  

	3.	 Remuneration 

  

	3.1	 The provisions of the MASTER AGREEMENT shall continue to apply to the ordering of any PROJECTS and billing of
the PROJECT SERVICES. The provisions of the MASTER AGREEMENT regarding the remuneration for PROJECT SERVICES shall also apply to TRON ACTIVITIES (except for those TRON ACTIVITIES performed in collaboration with one or more third parties) for which
the PARTIES have not concluded individual orders pursuant to section 2.1 of the MASTER AGREEMENT or defined as being included in the overall project plan pursuant to section 2.2 of the MASTER AGREEMENT. However, as compensation for the rights of use
granted in accordance with section 4 of this Supplementary Agreement, the PARTIES agree that TRON shall pay BIONTECH a sales-based remuneration in the amount as owed by BIONTECH to TRON in accordance with section 5.5 of the MASTER AGREEMENT. The
relevant provisions of the MASTER AGREEMENT, in particular sections 5.5, 5.7 and 5.8, shall apply, mutatis mutandis, to billing, documentation and payment. 

 

	3.2	 The PARTIES will agree upon an overall estimated order volume per CALENDAR YEAR for TRON ACTIVITIES (except for
those TRON ACTIVITIES performed in collaboration with one or more third parties) to be contracted for under the MASTER AGREEMENT as PROJECT SERVICES. If the overall actual volume of such TRON ACTIVITIES performed for a CALENDAR YEAR exceeds the
overall order volume for such CALENDAR YEAR, the PARTIES shall take all efforts to agree upon any deviating remuneration regulations in respect of section 3.1, sentence 2, of this Supplementary Agreement. 

 

	4.	 TRON’s rights of use 

 

	4.1	 In deviation from section 4.1 of the MASTER AGREEMENT, the companies of the BIONTECH GROUP shall grant TRON and
TRON AFFILIATED COMPANIES a non-exclusive, non-transferable, non-sublicensable, cost-free, perpetual (except to the TRON AFFILIATED COMPANIES only as long as they are affiliated with TRON) and in evocable license: (a) to use the RESULTS solely

  
 Page 7 

 EXECUTION COPY 
  

	 	for internal non-commercial research conducted by and within TRON and/or TRON AFFILIATED COMPANIES; and (b) to the extent the RESULTS (i) have been specified in the
Attachment 4.1 as attached to this Supplementary Agreement or (ii) have been otherwise mutually agreed upon by TRON and BIONTECH to be included in Attachment 4.1 to this Supplementary Agreement by amendment to Attachment 4.1 or as
otherwise agreed in writing, to use such RESULTS in collaboration with academic and nonprofit institutions, and to disclose (under an appropriate obligation to confidentiality) such RESULTS (but not any source code, unless otherwise agreed) to such
academic and nonprofit institutions, solely for use by such academic and nonprofit institutions in non-commercial research . TRON is aware that BIONTECH has duties to obtain agreement from third party collaborators, such as [***] or [***], regarding
the use or disclosure of such results. 

 For the avoidance of doubt, TRON and TRON AFFILIATED COMPANIES shall not be
restricted to use and disclose the supporting [***] as specified in Attachment 4.1 and any other RESULTS to the extent that such [***] and/or RESULTS have been published or otherwise enter the public domain through no fault of TRON or TRON
AFFILIATES COMPANIES in breach of its duty of secrecy in accordance with the MASTER AGREEMENT or through no fault of TRON or TRON AFFILIATES COMPANIES in breach of its duty to obtain agreement to use or disclose RESULTS. TRON is aware that BIONTECH
has duties to obtain agreement from third party collaborators, such as [***] or [***], regarding the use or disclosure of such results. For clarity, the use of any supporting [***] or any other RESULTS in a clinical trial or otherwise for the
diagnosis or treatment of patients, in each case without publicly disclosing such [***] or RESULTS, shall not constitute such RESULTS entering the public domain for the purposes of the MASTER AGREEMENT and this Supplementary Agreement. 

For the further avoidance of doubt: section 2.2 of this Supplementary Agreement shall apply to the results generated using the licenses granted
in this section 4.1 (whether generated by TRON or TRON AFFILIATED COMPANIES or by academic or nonprofit institutions in collaboration with TRON or TRON AFFILIATED COMPANIES). With the exception of the right to disclose the RESULTS under 4.1 (b) to
academic or nonprofit institutions in the scope of the license under section 4.1 (b), the duty of secrecy regarding the RESULTS m accordance with the MASTER AGREEMENT shall not be affected. 

  
 Page 8 

 EXECUTION COPY 
  

 

	4.2	 Further, in deviation from section 4.1 of the MASTER AGREEMENT, the companies of the BIONTECH GROUP grant TRON
and TRON AFFILIATED COMPANIES a non-exclusive, non-transferable, non-sublicensable, cost-free, perpetual (except to the TRON AFFILIATED COMPANIES only as long as they are affiliated with TRON) and irrevocable license under the supporting [***] as
specified in Attachment 4.1 and any other RESULTS for the research, development and performance of diagnostic services, to the extent that these diagnostic services are provided solely to direct patient customers and medical care centers solely for
the clinical care of patients, but not to any other entities, including drug manufacturers or manufacturers of medical devices and research-based pharmaceutical companies. For the avoidance of doubt, these diagnostic services shall not include the
provision of any analysis or results related to [***]. Section 2.2 of this Supplementary Agreement shall apply to the results generated by TRON or TRON AFFILIATED COMPANIES using the license granted in this section 4.2. 

 

	4.3	 TRON will notify BIONTECH immediately, once TRON or a TRON AFFILIATED COMPANY commences to offer diagnostic
services. For the avoidance of doubt: The regulations regarding confidential treatment, scientific publications, presentations and lectures set forth in section 7 of the [***] AGREEMENT shall apply, mutatis mutandis, to the RESULTS.

  

	5.	 Rights to improvements to [***] DEVELOPMENT RESULTS as well as post-contractual rights

  

	5.1	 The PARTIES hereby agree that, from [***] October 18, 2016, through the term of this Supplementary Agreement,
with respect to all research and development activities of TRON and/or TRON AFFILIATES COMPANIES outside the [***] COOPERATION FIELD (i) that are not contracted for under the MASTER AGREEMENT as PROJECT SERVICES and (ii) that generate
improvements to [***] Entwicklungsergebnisse (as defined in the [***] AGREEMENT and hereinafter referred to as “[***] DEVELOPMENT RESULTS”) or results that are otherwise necessary or useful for the research or development of [***], which
are developed solely or jointly by TRON or TRON AFFILIATED COMPANIES, TRON herewith grants BioNTech RNA Pharmaceuticals GmbH an exclusive perpetual, irrevocable, transferable license, with the right to grant sub-licenses, under such
improvements or results for the purposes of the research, development, manufacture or 

  
 Page 9 

 EXECUTION COPY 
  

	 	commercialization of [***]; provided, however insofar as the rights to such improvement or results were generated by TRON and/or TRON AFFILIATED COMPANIES in collaboration with one or more third parties, such
license shall be subject to any rights of such third parties. 

 Accordingly, a separate transfer or licensing agreement, as
stipulated in section 8 of the [***] AGREEMENT, is not necessary for improvements to the [***] DEVELOPMENT RESULTS that are generated prior to the end of the term of this Supplementary Agreement to the MASTER AGREEMENT. Section 8 of the [***]
AGREEMENT is therefore deleted in its entirety by this Supplementary Agreement. 
  

	5.2	 During the term and for a period of three (3) years after the expiry or termination of this Supplementary
Agreement, TRON undertakes not to perform any research or development activities in the [***] COOPERATION FIELD in collaboration with commercial third parties nor to grant licenses for, or otherwise provide, results or technologies of TRON or TRON
AFFILIATED COMPANIES for the use in this area to such third parties. TRON shall also ensure that TRON AFFILIATED COMPANIES will, except as permitted by the licenses granted in sec. 4, not enter into such collaboration agreements or grant any
licenses or services. During the term of this Supplementary Agreement, in the event TRON undertakes to perform any research or development activities in the [***] COOPERATION FIELD in collaboration with third parties other than commercial third
parties as permitted under section 4, TRON and BIONTECH will, subject to any confidentiality obligations towards the relevant third parties, inform each other about industrial property rights or copyrights of third parties which they m-e aware of or which become known to them and which might be violated by the use of the RESULTS. 

  

	5.3	 With respect to all results generated by TRON or TRON AFFILIATED COMPANIES within four (4) years from the
expiry or termination of this Supplementary Agreement (a) from the performance of activities in the [***] COOPERATION FIELD or (b) that are improvements to [***] DEVELOPMENT RESULTS or are otherwise necessary or useful for the research or
development of [***], in each case, that are not otherwise contracted for under the MASTER AGREEMENT as PROJECT SERVICES, TRON herewith grants BioNTech RNA Pharmaceuticals GmbH a non-exclusive, royalty-free, fully paid-up, perpetual,
irrevocable, transferable license, with the right to grant sub-licenses, under such results for the purposes of the research, development, manufacture or 

  
 Page 10 

 EXECUTION COPY 
  

	 	commercialization of [***]; provided, however that to the extent improvements to [***] DEVELOPMENT RESULTS have been generated by TRON and/or any TRON AFFILIATED COMPANY in collaboration with one or more third
parties outside the [***] COOPERATION FIELD, the aforementioned license grant by TRON to BioNTech RNA Pharmaceuticals GmbH shall be subject to any rights of third parties. As regards to the results from the development and research activities of
TRON AFFILIATED COMPANIES, this shall only apply insofar as the relevant TRON AFFILIATED COMPANY perform such activities (i) pursuant to the licenses under the patents listed under Attachment 2.1 and related BioNTech Development Results
(defined as “BioNTech – Entwicklungsergebnisse” under Section 1.3 of the LICENSE AGREEMENT) granted under section 3.6 of the LICENSE AGREEMENT, (ii) pursuant to the licenses granted under section 4(a) or 4(b) of the
[***] AGREEMENT or section 4.1 or 4.2 of this Supplementary Agreement or (iii) otherwise using or incorporating the RESULTS (as defined by section 1.3 of the MASTER AGREEMENT and as amended by the [***] Agreement and this Supplementary Agreement),
which includes the [***] DEVELOPMENT RESULTS (as defined by the [***] AGREEMENT). 

  

	5.4	 Except in the case of results specified in section 5.3 generated by academic or nonprofit institutions in
collaboration with TRON or TRON AFFILIATE D COMPANIES using the licenses granted in section 4.1 (in which case only section 5.3 shall apply), TRON will in addition to section 5.3 negotiate in good faith to transfer the results, or exclusively
license the results, specified in section 5.3 to BioNTech RNA Pharmaceuticals GmbH at reasonable terms and conditions, which take reasonable account of the contributions made by the PARTIES in developing such results. BioNTech RNA Pharmaceuticals
GmbH may accept this offer for each result by a written declaration to be provided within 60 (sixty) days from a written notice of the relevant result. Provided that BioNTech RNA Pharmaceuticals GmbH accepts the transfer or the exclusive right of
use, the royalty obligations specified in the MASTER AGREEMENT shall apply to the payment obligations of BioNTech RNA Pharmaceuticals GmbH vis-a-vis TRON. TRON’s rights of use pursuant to section 4 of this Supplementary Agreement shall also
apply to any results transferred or licensed in this manner. The aforementioned obligation to offer is restricted to results that are generated within four (4) years from the expiry or termination of this Supplementary Agreement.

  

	6.	 Development of [***] with [***] 

  
 Page 11 

 EXECUTION COPY 
  

In the context of the performance of PROJECT SERVICES for the companies of the BIONTECH GROUP in the [***] COOPERATION FIELD that contain the
development and validation of [***] and have now entered the design input phase, such design input phase as defined in SOP 081-009 or any amended or successor version, TRON shall not, without the prior written consent of BIONTECH, use any [***] or
other materials in a form or manner which creates, or purports to create, obligations (a) for a licensee to license its own intellectual property rights, including patents, to any third parties or (b) that a licensee’s [***] or other materials
must: (i) be disclosed or distributed in [***] form; (ii) be licensed for the purpose of making derivative works; or (iii) be redistributable at no charge (hereinafter referred to as “[***]”). Prior to using any [***] in the performance of
PROJECT SERVICES that contain the development and validation of [***] and have now entered the design input phase, such design input phase as defined in SOP [***] or any amended or successor version, TRON will allow BIONTECH to review in advance the
conditions of use of [***] that TRON intends to use and TRON will not use any such [***] until BIONTECH has approved the use of such [***]. In any case, regarding the use by TRON of [***] approved by BIONTECH in the performance of PROJECT SERVICES
that contain the development and validation of [***] and have now entered the design input phase, such design input phase as defined in SOP [***] or any amended or successor version, TRON will set up standard work instructions, to be proposed and
ultimately approved by BIONTECH, which shall ensure, as far as possible, functional and formal independence of one’s own developments vis-a-vis the [***] parts of [***] (e.g. by specifying that [***]) and which shall include standard work
instructions that are substantially similar to SOP [***] or any amended or successor version. If TRON wants to engage TRON AFFILIATED COMPANIES as a subcontractor for the performance of PROJECT SERVICES, this is only permitted if (i) TRON has
notified in writing BioNTech of such TRON AFFILIATED COMPANIES and (ii) such TRON AFFILIATED COMPANIES have also implemented such work instructions beforehand. In no event may TRON engage third parties (other than TRON AFFILIATED COMPANIES as
permitted above) for the performance of PROJECT SERVICES without the prior written consent of BIONTECH. 
  

	7.	 TNBC-MERIT Study 

  
 Page 12 

 EXECUTION COPY 
  

On 01 December 2013, BIONTECH and TRON concluded a “service agreement for bioinformatic identification of mutations in human tissue
samples as part of GAPVAC and TNBC-MERIT”. BIONTECH and TRON hereby clarify that the services conducted by TRON for the clinical study “TNBC-MERIT” under such service agreement shall, as of 18 October 2016, be provided in the context
of the [***] and BIONTECH and TRON agree that the provisions of the MASTER AGREEMENT, as supplemented by the [***] AGREEMENT and this Supplementary Agreement, shall apply in respect of the results generated by TRON in providing the services for the
clinic al study “TNBC-MERIT”. 
  

	8.	 Term of this Supplementary Agreement 

 

	8.1	 This Supplementary Agreement shall be effective and in force (as a supplement to the MASTER AGREEMENT) for a
fixed term from 01.01.2017 to 31.12.2019 in deviation from section 8.1 of the MASTER AGREEMENT, provided that BioNTech may terminate this Supplementary Agreement after 30.06.2018 upon six (6) months’ prior written notice. If this Supplementary
Agreement has not terminated before the expiration of the fixed term of this Supplementary Agreement, the PARTIES will agree upon a potential extension and the relevant terms and conditions in good time prior to the expiry of this Supplementary
Agreement. If, in the event of an earlier termination of this Supplementary Agreement, TRON incurs any costs for the reduction of structures/personnel or any remaining costs that cannot be reduced in the short term, BIONTECH will pay 50% of these
costs, whereby the cost share will not amount to more than €217,000 (in words: two-hundred seventeen thousand euro). Sentence 1 and sentence 3 of Section 3.1, 4.1, 4.2, 4.3, 5.2, 5.3, 5.4, 7, 8.2, 8.3, and 8.4 shall survive the expiration or
earlier termination of this Supplementary Agreement in accordance with the terms set forth therein. In addition, Section 6 shall survive any expiration (but not earlier termination) of this Supplementary Agreement in accordance with the terms set
forth therein. 

  

	8.2	 Section 8.2, sentence 2, of the MASTER AGREEMENT continues to apply to the termination of individual
PROJECTS. 

  
 Page 13 

 EXECUTION COPY 
  

 

	8.3	 In deviation from section 8.5 of the MASTER AGREEMENT, the termination of the MASTER AGREEMENT by BIONTECH
pursuant to section 8.1 above shall apply to all companies of the BIONTECH GROUP. 

  

	8.4	 Section 8.3, 8.4 and 8.6 of the MASTER AGREEMENT shall not be affected. 

 

	9.	 Final Provisions 

This Supplementary Agreement is an integral part of the MASTER AGREEMENT. To the extent of any conflicts with the MASTER AGREEMENT or the [***] AGREEMENT, this
Supplementary Agreement shall take precedence. Unless otherwise set forth in this Supplementary Agreement, the provisions of the MASTER AGREEMENT and the [***] AGREEMENT continue to apply unchanged. The MASTER AGREEMENT, supplemented by this
Supplementary Agreement and the [***] AGREEMENT, is the contractual basis of the [***]-related collaboration between the companies of the BIONTECH GROUP and TRON, unless TRON and the companies of the BIONTECH GROUP agree explicitly and in writing
upon deviating general terms in the individual case. The written individual orders concluded previously on the basis of the MASTER AGREEMENT continue to exist unchanged. 

- Signature pages below - 

  
 Page 14 

 EXECUTION COPY 
  

			
	BIONTECH AG
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  

			
	BioNTech RNA Pharmaceuticals GmbH
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  
 Page 15 

 EXECUTION COPY 
  

 

			
	BioNTech Diagnostics GmbH
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  

			
	BioNTech Protein Therapeutics GmbH
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  

			
	BioNTech Cell & Gene Therapies GmbH
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  

			
	BioNTech Innovative Manufacturing Services GmbH
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  
 Page 16 

 EXECUTION COPY 
  

 

			
	JPT Peptide Technologies GmbH
		
	By:	 	[***]
		
	Name:	 	[***]
		
	Title:	 	[***]

  

									
	 TRON-Translationale Onkologie
 an
der Universitätsmedizin der Johannes Gutenberg – Universität Mainz gemeinnützige

					
	By:	  	[***]	  		  	By:	  	[***]
					
	Name:	  	[***]	  		  	Name:	  	[***]
					
	Title:	  	[***]	  	            	  	Title:	  	[***]

  
 Page 17 

 EXECUTION COPY 
  

Attachment 2.1 
  

			
	 BioNTech Reference No.
	  	 Internat. Application No.

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 Including any patents and patent applications derived from the foregoing patent applications in any country in the world,
including any continuations, continuations-in-part, divisions, provisionals or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexaminations, renewals or extension (including supplemental
protection certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all non-United States counterparts of any of the foregoing. 

  
 Page 18 

 EXECUTION COPY 
  

Attachment 4.1 

Initial schedule of RESULTS under section 4.1 (b) (i) 

[***]: 
 The specified RESULTS include any [***] updates or
upgrades to the supporting [***] listed in the table above and those can be used and disclosed as incorporated in the [***] by TRON and TRON AFFILIATED COMPANIES in accordance with section 4.1 (b) of the Supplementary Agreement, except for any such
updates or upgrades that are improvements that impact, as reasonably determined by BioNTech after discussions with TRON, [***] or [***] or any such updates or upgrades that use, incorporate or otherwise are based upon CONFIDENTIAL INFORMATION of
BIONTECH (which may include confidential information from any third party collaborator of BIONTECH, such as [***]) (unless otherwise stated in section 4.1 or otherwise mutually agreed in accordance with section 4.1 (b) (ii) of the Supplementary
Agreement). 

  
 Page 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]